The epidemiology of the disease is strikingly concentrated in early childhood. Roughly 90 percent of pediatric cases present between the ages of 2 and 14, with a mean age of onset between 7.3 and 8.8 years. Clinicians classify morphea into several subtypes, including circumscribed plaque disease, linear morphea, generalized morphea, pansclerotic morphea, and mixed forms. Linear morphea is the most common subtype in children, and it is also among the most feared. When linear lesions cross the forehead and frontotemporal region, a presentation known as en coup de sabre, patients face a heightened risk of neurological involvement, facial asymmetry, and permanent deformity of the underlying skull and bone during critical growth windows. A related variant, Parry Romberg syndrome, can produce progressive hemifacial atrophy with or without visible skin hardening.

What makes morphea particularly dangerous in children is that it is not merely a skin disease. Approximately 20 percent of patients develop extracutaneous manifestations, including arthritis, uveitis, and neurological symptoms. Because the disease can scar actively growing bones and the developing skull, experts emphasize prompt and aggressive systemic treatment for deep or linear subtypes. Differentiating morphea from systemic sclerosis is also crucial: systemic sclerosis is characterized by sclerodactyly, Raynaud’s phenomenon, nail-fold capillary changes, telangiectasias, and internal organ involvement, features that generally distinguish it from the localized form. Interestingly, about half of morphea cases may undergo spontaneous resolution, complicating decisions about how intensively to treat.

The pathogenesis of morphea involves a complex interplay between genetic susceptibility, immune dysregulation, vascular injury, and aberrant fibrotic responses. Early lesions show a perivascular and interstitial inflammatory infiltrate of lymphocytes, macrophages, and plasma cells, accompanied by endothelial cell injury and microvascular dysfunction. Fibrosis itself is driven by persistent fibroblast activation and excessive deposition of type I and type III collagen. At the center of this process sits transforming growth factor-beta, or TGF-β, a master regulator that promotes fibroblast proliferation, drives differentiation into myofibroblasts, and boosts collagen synthesis while suppressing matrix degradation. Additional profibrotic mediators, including connective tissue growth factor, platelet-derived growth factor, and endothelin-1, amplify the fibrotic cascade.

Recent immunological insights have opened the door to precision therapies. A predominance of Th2-associated cytokines, particularly interleukin-4 and interleukin-13, promotes fibrosis through direct stimulation of fibroblast activity, and both cytokines signal through the Janus kinase-STAT pathway, especially STAT6. This provides a biological rationale for drugs targeting IL-4/IL-13 signaling, such as dupilumab, and for broader JAK-STAT inhibition. Even more dramatic was the discovery of novel gain-of-function STAT4 variants, inherited in an autosomal dominant manner or arising de novo, in children with disabling pansclerotic morphea, the most severe deep form of the disease. In a landmark study, four affected individuals from three families treated with oral ruxolitinib showed resolution of inflammatory biomarkers and clinical symptoms, with single-cell RNA sequencing revealing an immunodysregulatory signature that was effectively modulated by JAK inhibition.

For the majority of patients, treatment still follows a severity-based algorithm developed by the Childhood Arthritis and Rheumatology Research Alliance, or CARRA. Low-severity disease, defined as circumscribed superficial morphea without subcutaneous atrophy, extracutaneous involvement, or scalp hair loss, can be managed with high-potency topical corticosteroids, topical tacrolimus, calcipotriol, or imiquimod, often combined with phototherapy using broadband UVA, UVA1, or narrowband UVB. Tacrolimus ointment 0.1 percent demonstrated significant improvement in a randomized placebo-controlled trial after 12 weeks, while a case report of topical ruxolitinib cream 1.5 percent and another of the pan-JAK inhibitor delgocitinib in a 2-year-old suggest that topical JAK blockade may soon join the armamentarium. Imiquimod, an immune response modifier that induces interferon-gamma release and inhibits fibroblast collagen production, reduced lesion thickness in a prospective open-label study of nine children.

Moderate to severe disease demands systemic therapy, and methotrexate remains the undisputed first line. Dosing is calculated either by weight, at 0.3 to 0.6 mg/kg/week orally or up to 1 mg/kg/week subcutaneously, or by body surface area at 15 mg/m²/week, generally capped at 25 mg per week. Subcutaneous administration is often preferred for superior bioavailability and fewer gastrointestinal side effects. A systematic review found methotrexate effective in 93 percent of children, compared with 71 percent for phototherapy alone, and a randomized double-blind placebo-controlled trial showed that methotrexate combined with an initial prednisone course produced significantly better outcomes than placebo. Treatment is typically maintained for 12 to 24 months before tapering, and pulsed intravenous methylprednisolone may be added for severe or rapidly progressive cases, with side effects such as Cushingoid facies generally reversible after tapering.

For children who fail methotrexate, several alternatives have emerged. Mycophenolate mofetil achieved remission in 35 percent of patients within one year in a retrospective cohort, and in a separate study 90.9 percent of methotrexate-refractory children attained sustained remission over a mean follow-up of 9.4 years. Abatacept, which blocks T-cell costimulation, produced clinical improvement in 83 percent of eighteen refractory pediatric patients over 12 months, with some maintaining response to 24 months. Tocilizumab, an interleukin-6 receptor antagonist, significantly improved disease activity scores in five resistant patients after six months, though damage and quality-of-life measures did not change. Infliximab and the JAK inhibitors tofacitinib and baricitinib have each shown benefit in small case series, with tofacitinib reducing modified Localized Scleroderma Skin Activity Index and Damage Index scores without reported adverse effects.

The review’s authors caution that evidence for these emerging agents rests largely on case reports and small series, precluding definitive conclusions about comparative efficacy and long-term safety. Methotrexate and systemic corticosteroids remain the standard of care despite known risks including systemic toxicity and decreased bone density. Monitoring is especially critical in children, where corticosteroids can suppress growth velocity and bone mineral accretion. Objective assessment tools are improving: the Morphea Activity Measure correlates well with physician global assessments, and a novel multispectral imaging device using a handheld Antera 3D camera can predict new or enlarging lesions within three months with 90 percent sensitivity and 100 percent specificity, even in darkly pigmented skin. Ultrasound, magnetic resonance imaging, and 3D imaging add further objective windows into deep tissue involvement.

Finally, the review underscores that morphea is a whole-child disease. Although standardized quality-of-life instruments often show minimal impairment, qualitative studies of 690 pediatric patients across 13 studies reveal elevated stress, low self-worth, feelings of being different, and experiences of bullying tied to visible skin changes and treatment burden. The authors call for disease-specific psychosocial instruments, multidisciplinary care involving dermatology, rheumatology, physical therapy, psychology, and, for craniofacial disease, neurology, ophthalmology, and maxillofacial specialists, alongside standardized outcome metrics, robust disease registries, and personalized medicine approaches that tailor therapy to each child’s genetic and immunologic profile. As targeted therapies mature, the prospect of controlling fibrosis before it inflicts irreversible damage on growing bodies is moving steadily closer to reality.

Subject of Research: Advances in the diagnosis and treatment of pediatric morphea (localized scleroderma)

Article Title: Advances in the management of pediatric morphea: a narrative review

Article References: Kashyap, A., Jafari, A. J., Klimas, N., Koshelev, M., Mays, S. R., & Hebert, A. A. (2026). Advances in the management of pediatric morphea: a narrative review. Archives of Dermatological Research, 318(1), Article 448. https://doi.org/10.1007/s00403-026-04890-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04890-3

Keywords: pediatric morphea, localized scleroderma, autoimmune disease, methotrexate, JAK inhibitors, biologic therapy, fibrosis, STAT4, tocilizumab, abatacept, multidisciplinary care, skin disease

The research, led by Faezeh Khorasanizadeh of the Department of Radiology at Razi Hospital, Tehran University of Medical Sciences, together with colleagues in dermatology, epidemiology, and biostatistics, and in collaboration with Ximena Wortsman of the Universidad de Chile, a pioneer in cutaneous ultrasound, enrolled eighteen patients with newly biopsy-confirmed morphea. Every participant had at least one clinically active plaque at baseline. The investigators deliberately designed the protocol to be practical: rather than imaging every lesion, they selected the most clinically probable active plaque in each patient and compared it with adjacent or contralateral normal skin serving as an internal control. Each patient then underwent grayscale ultrasound, color Doppler ultrasound, and shear-wave elastography at the start of the study and again after six months of treatment, alongside standardized clinical scoring. The study received ethical approval from the institutional review board of Tehran University of Medical Sciences and was conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from all participants and guardians of minors.

The technical logic behind the imaging approach is worth unpacking. High-frequency grayscale ultrasound can resolve the individual layers of the skin with millimeter precision, allowing radiologists to measure dermal thickness, the hallmark of fibrotic thickening in morphea, and hypodermal thickness, which reflects the fat layer beneath. In active lesions, inflammation and edema typically thicken the dermis and can alter the echotexture of the subcutis. Color Doppler ultrasound adds a functional dimension by detecting blood flow; increased vascularity within and beneath a plaque is considered a marker of subclinical inflammatory activity that may persist even when the skin surface appears quiescent. Shear-wave elastography, the most technically sophisticated of the three, works by generating shear waves, a form of transverse mechanical vibration, within the tissue and measuring the speed at which they propagate. Because stiffer tissue transmits shear waves faster than soft tissue, the technique yields a quantitative estimate of tissue elasticity in kilopascals, turning the subjective sensation of hardened skin into a reproducible number.

After six months of follow-up, the results told a clear and clinically meaningful story. Dermal thickness, measured ultrasonographically, decreased significantly alongside a significant fall in mean clinical scores, with p values below 0.05. The LoSAI activity score dropped from a mean of 4.28 plus or minus 3.28 at baseline to 1.44 plus or minus 1.75 after treatment, while the LoSDI damage score declined from 11.39 plus or minus 7.38 to 9.56 plus or minus 6.77. Hypodermal thickness also decreased and skin elasticity increased slightly over the six months, but neither of these secondary changes reached statistical significance. The pattern makes biological sense: inflammation-driven dermal thickening responds to immunosuppressive therapy within months, whereas fibrotic remodeling of the subcutis and restoration of elastic properties are slower processes that may lag behind clinical improvement or, in the case of established damage, never fully reverse.

Perhaps the most intriguing findings emerged from the correlation analyses. Hypodermal thickness correlated negatively with the Physician Global Assessment of Damage, with a Spearman rho of -0.410 and a p value of 0.027, and positively with the LoSAI activity index, with rho of 0.513 and p of 0.004. Hypodermal thickness was also positively correlated with the Physician Global Assessment of Activity before treatment began. After therapy, hypodermal stiffness measured by elastography correlated positively with the LoSDI damage index. Taken together, these relationships suggest that the subcutaneous fat layer, often overlooked in favor of the dermis, carries real diagnostic information: a thicker hypodermis tracks with active disease, while stiffer subcutaneous tissue tracks with accumulated damage. This positions elastography not merely as a research curiosity but as a potential bridge between the activity and damage domains that clinicians must distinguish when deciding whether to escalate, continue, or taper therapy.

Not every result favored the new technology, and the authors were candid about the limitations. When radiologists and dermatologists independently rated disease activity using shear-wave elastography and color Doppler, the inter-rater agreement was poor, with a kappa of just 0.053, barely above chance. This discordance likely reflects the steep learning curve of cutaneous ultrasound, differences in probe positioning and pressure, and the absence of universally standardized scoring protocols across specialties. It is a sobering reminder that a measurement technique is only as objective as the protocol governing its use. The authors also emphasized that their cohort was small, with only eighteen patients, all of whom had plaque-type or linear morphea, the most common subtypes. Generalizing to rarer variants such as generalized, deep, or pansclerotic morphea will require larger and more diverse cohorts, and the six-month follow-up window may be too short to capture slower changes in elasticity and subcutaneous architecture.

Why does an objective biomarker matter so much for morphea specifically? Current treatment typically involves systemic corticosteroids combined with methotrexate or, increasingly, other immunomodulators, a regimen that carries real toxicity and demands months of commitment. Because clinical scores are subjective and damage can masquerade as activity, physicians risk both overtreating patients whose disease has already burned out and undertreating those with smoldering subclinical inflammation that continues to cause irreversible fibrosis. Ultrasound-based measures could change this calculus in several ways: by providing early, quantitative evidence of response within weeks rather than months; by identifying subclinical activity that warrants continued therapy even when the skin looks better; and by serving as surrogate endpoints in clinical trials, where the rarity of morphea has long made adequately powered studies difficult. Prior work by Wortsman and colleagues on the Ultrasound Morphea Activity Scoring system, and by other groups applying shear-wave elastography in both localized and systemic scleroderma, has laid the groundwork, but this study is among the first to track patients longitudinally through treatment with a multimodal protocol.

The study also fits into a broader movement in dermatology toward quantitative, imaging-based assessment of skin disease. Thermal imaging has been explored for detecting inflammation in localized scleroderma, dermoscopy offers clues to disease stage, and 50-megahertz ultrasound has documented improvement after ultraviolet A1 phototherapy. In systemic sclerosis, elastography is being evaluated as a measure of skin strain and fibrosis severity, raising the possibility of a shared imaging vocabulary across the sclerosing diseases. A recent consensus statement on the diagnosis and treatment of sclerosing skin diseases underscores how much remains unsettled in monitoring these conditions, and the authors of the current study position their work as a preliminary but prospective step toward filling that gap with tools that are already available in most radiology departments.

For now, the take-home message is measured but promising. In this preliminary prospective cohort, dermal thickness measured with high-frequency ultrasound emerged as the strongest candidate for an objective marker of treatment response in morphea, while color Doppler and shear-wave elastography showed potential as adjunctive tools whose clinical utility remains exploratory. The authors themselves stress that validation in larger cohorts is essential before these techniques enter routine practice, and the poor inter-rater agreement highlights the need for standardized acquisition and scoring protocols, ideally with dedicated training for both radiologists and dermatologists. Still, the direction of travel is unmistakable. If subsequent studies confirm these findings, the era of guessing whether a morphea plaque is truly quiet could give way to an era in which a handheld probe, a quantitative elasticity map, and a few millimeters of measured dermis tell clinicians exactly what the immune system is doing beneath the skin, and whether the treatment they have chosen is actually working.

Subject of Research: Ultrasound and shear-wave elastography for monitoring treatment response in morphea

Article Title: Ultrasound and shear-wave elastography as a tool for evaluating response to treatment of morphea: a preliminary report of a prospective study

Article References: Khorasanizadeh, F., Sharifi, M. A., Vahabi, S. M., Ansari, M. S., Ghandi, N., Hosseini, F., Etesami, I., & Wortsman, X. (2026). Ultrasound and shear-wave elastography as a tool for evaluating response to treatment of morphea: a preliminary report of a prospective study. Archives of Dermatological Research, 318(1), Article 457. https://doi.org/10.1007/s00403-026-04919-7

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04919-7

Keywords: morphea, localized scleroderma, ultrasound, shear-wave elastography, color Doppler, dermal thickness, LoSAI, LoSDI, treatment response, biomarkers, dermatology, skin fibrosis

Localized scleroderma, also called morphea, remains one of the most stubborn fibrotic skin diseases. It causes induration of the dermal and subcutaneous layers, and in severe cases leads to ulcers, disfiguring lesions, joint deformity, restricted movement, and even elevated fracture risk later in life. Current treatment relies mainly on immunosuppressants and glucocorticoids, with emerging options such as tocilizumab and JAK inhibitors, but no available therapy can reverse established skin fibrosis. That therapeutic gap drove the Sichuan team to look deeper into the molecular machinery that keeps fibroblasts, the collagen-producing cells of the dermis, locked in an activated, scar-forming state.

Their starting point was mitochondria. Previous work has established that mitochondrial dysfunction is a core driver of fibroblast activation in scleroderma, and that oxidative stress, a consequence of damaged mitochondria, plays an important role in the disease. Mitochondria are the main source of reactive oxygen species inside cells, and when their calcium handling goes awry, these reactive molecules accumulate and push cells toward senescence, a state of permanent growth arrest. Senescent cells then secrete a cocktail of inflammatory signals known as the senescence-associated secretory phenotype, which promotes fibroblasts and macrophages to adopt a fibrotic phenotype and fuels the scarring process.

Central to mitochondrial calcium control is a structure called the mitochondria-associated endoplasmic reticulum membrane, or MAM. At these contact sites, a channel complex composed of the proteins IP3R1, GRP75, and VDAC1 ferries calcium ions from the endoplasmic reticulum into mitochondria. When this flux becomes excessive, mitochondrial calcium overload damages the organelles, collapses their membrane potential, and elevates production of mitochondrial reactive oxygen species. Using transmission electron microscopy on skin samples from patients treated at West China Hospital between 2024 and 2025, the researchers found that the spatial proximity between the endoplasmic reticulum and mitochondria was significantly reduced in morphea lesions compared with healthy control tissue, providing the first preliminary evidence that MAM homeostasis is disturbed in this disease.

To find a drug that could restore that balance, the team turned to parthenolide, which has documented anti-inflammatory, antioxidative, and antifibrotic effects in liver, lung, kidney, and peritoneal fibrosis models. In human dermal fibroblasts stimulated with TGF-β, the master cytokine of fibrosis, parthenolide treatment reduced the number of β-galactosidase-positive senescent cells, increased proliferation as measured by EdU incorporation, and downregulated the senescence markers p21 and p16 along with the inflammatory cytokines IL-6, IL-1β, and TNF-α. At the highest concentration tested, 5 micromolar over 48 hours, the compound also lowered mRNA and protein levels of α-smooth muscle actin and type I collagen, the hallmarks of myofibroblast activation. Notably, the effects were concentration-dependent, with anti-aging effects appearing at medium and high doses and antifibrotic effects at high doses. When the researchers cleared senescent cells using the dasatinib and quercetin combination, fibroblast activation also eased, supporting the idea that parthenolide relieves fibrosis at least in part by modulating senescence.

The mechanistic hunt then moved to the MAM itself. Confocal microscopy showed that parthenolide diminished the colocalization between mitochondria and the endoplasmic reticulum and increased the inter-organelle distance in activated fibroblasts, while flow cytometry revealed restored mitochondrial membrane potential and reduced reactive oxygen species. RNA sequencing identified 1,111 genes differentially expressed after TGF-β stimulation and 290 after parthenolide treatment, with 161 genes shared between the two sets. Enrichment analyses pointed to wound healing, collagen-containing extracellular matrix, and endoplasmic reticulum lumen pathways. To narrow the field, the researchers performed inverse virtual screening against roughly 2,600 protein structures from the Protein Data Bank, ranking candidates by binding free energy, and intersected the top 100 hits with their differentially expressed genes. Two genes emerged: PI16 and Ero1L.

Ero1L, an oxidoreductase enzyme that lives predominantly at the MAM and responds to hypoxia and oxidative stress, became the prime suspect. Molecular docking predicted that parthenolide binds Ero1L with a binding energy of −7.3 kilocalories per mole, and surface plasmon resonance on a Biacore instrument confirmed a direct physical interaction. Docking simulations highlighted two key residues, ARG-449 and PHE-62, and site-directed mutagenesis showed that converting ARG-449 to alanine abolished the binding affinity, while the PHE-62 mutation had no significant effect, confirming the specificity of the interaction. Parthenolide also reduced Ero1L mRNA and protein expression in TGF-β-treated cells. Single-cell RNA sequencing of a public dataset covering fourteen localized scleroderma patients and fourteen healthy controls, encompassing 32,154 cells clustered into fifteen cell types, showed that Ero1L is expressed at higher levels in activated fibroblasts than in other cell subtypes, and immunohistochemistry revealed elevated Ero1L in patient skin biopsies that correlated positively with both senescence markers and the modified Localized Scleroderma Skin Severity Index.

Causality tests sealed the case. When the researchers overexpressed Ero1L in fibroblasts, the protective effects of parthenolide were reversed: senescence and fibrosis markers climbed back up, mitochondrial reactive oxygen species rose, membrane potential fell, and the compound’s suppression of ER-mitochondrial colocalization was blunted. Conversely, knocking Ero1L down with siRNA mimicked the drug’s benefits, reducing fibrotic and senescent markers, restoring mitochondrial health, increasing the average ER-mitochondria distance on electron micrographs, and weakening the interactions within the IP3R1-GRP75-VDAC1 calcium channel complex. Parthenolide treatment similarly downregulated the three channel proteins and eased mitochondrial calcium overload, suggesting that Ero1L acts upstream of calcium flux at the MAM. The authors propose that Ero1L may also promote fibrosis indirectly through redox regulation, since the enzyme reoxidizes protein disulfide isomerase to maintain the disulfide bonds needed for type I collagen folding and secretion.

Because parthenolide’s poor water solubility and low bioavailability have hindered clinical use, the team engineered a delivery system combining PLGA nanoparticles loaded with the drug and a thermoresponsive F127 poloxamer hydrogel. Electron microscopy showed spherical nanoparticles, and rheological testing confirmed the hydrogel’s injectability and temperature-dependent gel transition at body temperature. High-performance liquid chromatography demonstrated a slower, sustained release without an initial burst phase, and live-dead staining and CCK-8 assays confirmed good biocompatibility. In a bleomycin-induced mouse model of localized scleroderma, weekly injections of the formulation, designated F127@PLGA@PTL at 70 milligrams per kilogram, significantly attenuated dermal thickness, collagen deposition, and myofibroblast counts, reduced Ero1L protein expression, and showed anti-aging effects, while multiplex immunofluorescence indicated the treatment specifically quieted activated fibroblasts without measurable effects on vascular endothelial cells, keratinocytes, or Th2 lymphocytes.

The study is the first to implicate Ero1L in the pathogenesis of localized scleroderma and to demonstrate an anti-aging effect of parthenolide in skin fibrosis, positioning the ER-mitochondrial interface as a therapeutic target for hardening skin diseases. The authors caution that their findings rest on cell culture and mouse models and require validation in human subjects, and they note that parthenolide can behave differently in other contexts, even inducing mitochondrial dysfunction in cancer cells, so its biological effects appear cell-specific and shaped by metabolic state. Still, by connecting a humble herbal compound, a calcium-handling hub, and an aging program into one mechanistic chain, the work opens a concrete path toward therapies that could do what current medicine cannot: soften fibrotic skin by rejuvenating the cells that build it.

Subject of Research: Parthenolide targeting of Ero1L to regulate mitochondria-associated ER membranes in localized scleroderma fibrosis and cellular senescence

Article Title: Targeting Ero1L by Parthenolide Alleviates Cellular Senescence and Fibrosis of Localized Scleroderma by Regulating Mitochondria‐Associated Endoplasmic Reticulum Membranes Stabilization

Article References: Wang, F., Xing, R., Xie, M., Qin, Y., Zhang, Y., Cao, D., He, G., & Lyu, X. (2026). Targeting Ero1L by Parthenolide Alleviates Cellular Senescence and Fibrosis of Localized Scleroderma by Regulating Mitochondria‐Associated Endoplasmic Reticulum Membranes Stabilization. Aging Cell, 25(10), Article e70738. https://doi.org/10.1111/acel.70738

Image Credits: AI Generated

DOI: 10.1111/acel.70738

Keywords: localized scleroderma, parthenolide, Ero1L, mitochondria-associated ER membranes, cellular senescence, fibrosis, calcium flux, dermal fibroblasts, PLGA nanoparticles, F127 hydrogel, oxidative stress, TGF-beta